Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SNA017
- Development stage
- Preclinical
- Lead developer
- SmartNuclide
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SNA017 is a radiopharmaceutical candidate developed by SmartNuclide (Suzhou SmartNuclide Biopharmaceutical) that targets the thyroid-stimulating hormone (TSH) pathway. It is being developed as a theranostic agent, encompassing both a diagnostic imaging component for solid tumors and a therapeutic component for the treatment of breast cancer and gastric cancer. The agent leverages the specificity of TSH-related markers to deliver radioisotopes for either visualization or targeted cytotoxicity. As of the latest pipeline updates, SNA017 is in preclinical development.
02
Targets
TSHR (Thyroid-stimulating hormone receptor)
Beyond the preview
Go deeper on SNA017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SNA017.